Abstract
Purpose. To evaluate the effect of a carbonic anhydrase inhibitor (brinzolamide 1%) on the short-term increase of intraocular pressure (IOP) after intravitreal injections (IVI) of an anti-VEGF drug in patients with neovascular AMD (nAMD). Material and methods. This study included 60 patients with newly diagnosed nAMD. In group 1 (30 people), prophylactic drugs were not used; in group 2 (30 people), brinzolamide 1% was instilled twice the day before the injection (at 8 pm) and on the day of injection 2 hours before the procedure (at 8 am). IOP was measured with an ICare Pro before IVI (T0), 1 minute after IVI (T₁), 30 minutes (T₂), 60 minutes (T₃). Results. Dynamic changes of IOP in all groups occurred with the same pattern: IOP increased immediately after IVI of the anti-VEGF drug, after 30 minutes IOP decreased and returned to the initial IOP level over the next 60 minutes. Brinzolamide 1% led to a statistically significant decrease in IOP immediately after injection during the first IVI by an average of 3.84 ± 5.1 [95 % CI 1.58–6.1] mm Hg. compared with the control group (p < 0.001), during the second IVI by 5.26 ± 5.7 [95 % CI 2.86–7.66] mm Hg (p < 0.001), by 5.49 ± 5.8 [95 % CI 3.1–7.88] mm Hg (p < 0.001) during the third IVI. Conclusions. Prophylactic instillation of carbonic anhydrase inhibitor (brinzolamide 1%) twice led to a statistically significant decrease in ocular hypertension immediately after IVI of anti-VEGF drug compared to the control group over three loading injections. Keywords: anti-VEGF drug, intraocular pressure, carbonic anhydrase inhibitor
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
